The partnership will give cancer centers across the country the ability to easily share information that can help enhance outcomes and expedite cancer research
According to NantHealth, the partnership is a milestone for Quantum Immuno-oncology Lifelong Trial (QUILT) program, designed to harness and orchestrate all the elements of the immune system by testing new combinations of vaccines, cell-based immunotherapy, metronomic chemotherapy, low dose radiotherapy and immunomodulators.
The companies will deploy the offerings across the Quality Cancer Care Alliance (QCCA) and the National Cancer Care Alliance (NCCA) sites over the next year.
Oncologists, throughout the network can use GPS Cancer, a molecular test offered by NantHealth that uses quantitative targeted proteomics detected by mass spectrometry with whole DNA and RNA sequencing, of both normal and cancer tissue.
On the other hand, TransMed will offer its Clinical Practice Suite that provides oncology practices with applications that can identify options for treatments and their historical outcomes for a group of similar patients.
Each of the patient population report will include the number of patients, the average survival of patients, the death rate and any other complications associated with a particular treatment. TransMed claims that this is possible through its Precision Medicine Platform, supported by other major consortiums around the world.
NantHealth founder and CEO Patrick Soon-Shiong said: “Oncologists throughout the country are constantly searching for trials that fit their specific patients’ needs. This initiative creates the opportunity for patients to access new and existing trials under the QUILT program.”
TransMed chairman and CEO Nick Berens said: “At TransMed Systems, we are constantly working to develop and deliver software tools that facilitate the analysis and application of translational data.
“We’re excited about the potential of this partnership and look forward to revolutionizing clinical trial identification and recruitment for the cancer community.”
